We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AFFYMAX AND TAKEDA ANNOUNCE COMPREHENSIVE GLOBAL AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF HEMATIDE FOR ANEMIA
AFFYMAX AND TAKEDA ANNOUNCE COMPREHENSIVE GLOBAL AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF HEMATIDE FOR ANEMIA
June 27, 2006
Affymax, Inc. and Takeda Pharmaceutical Company Limited today announced that
the companies have entered into an exclusive global agreement to develop and
commercialize Affymax's lead product candidate, Hematide, for the treatment
of anemia.
